Tenapanor
Tenapanor (pronounced as ten-a-pan-or) is a pharmaceutical drug used primarily for the treatment of Irritable Bowel Syndrome with constipation (IBS-C) and Hyperphosphatemia. It is marketed under the brand name Ibsrela for IBS-C and Auryxia for hyperphosphatemia.
Etymology
The name Tenapanor is a coined term, with no specific etymological roots. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.
Pharmacology
Tenapanor is a minimally absorbed small molecule that acts locally in the gut to inhibit the sodium/hydrogen exchanger 3 (NHE3), resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients. For hyperphosphatemia patients, it reduces the absorption of dietary phosphate.
Related Terms
- Irritable Bowel Syndrome: A common disorder that affects the large intestine. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both.
- Hyperphosphatemia: A condition of having too high a level of phosphate — a type of electrolyte — in your blood.
- Sodium/hydrogen exchanger 3 (NHE3): A protein that in humans is encoded by the SLC9A3 gene. It plays a critical role in the absorption of sodium in the intestines and kidneys.
- Phosphate: A chemical that contains the mineral phosphorus. Phosphates are important in metabolism.
See Also
External links
- Medical encyclopedia article on Tenapanor
- Wikipedia's article - Tenapanor
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski